Anna Eiring

Dr. Anna Eiring

Biological Sciences, The University of Texas at El Paso, El Paso, Texas, USA
orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2010 in Cell
Verified
Journal Article
Closed access
Anna EiringAnna Eiring
Anna Eiring
JHJason G. Harb
Jason G. Harb
PNPaolo Neviani
Paolo Neviani
CGChristopher Garton
Christopher Garton
JOJoshua J. Oaks
Joshua J. Oaks
DPDanilo Perrotti
Danilo Perrotti

1 September 2014 in Cancer Cell
Verified
Journal Article
Closed access
MZMatthew S. Zabriskie
Matthew S. Zabriskie
CEChristopher A. Eide
Christopher A. Eide
STSrinivas K. Tantravahi
Srinivas K. Tantravahi
NVNadeem A. Vellore
Nadeem A. Vellore
JEJohanna Estrada
Johanna Estrada
TOThomas O’hare
Thomas O’hare

4 September 2007 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
PNPaolo Neviani
Paolo Neviani
RSRamasamy Santhanam
Ramasamy Santhanam
JOJoshua J. Oaks
Joshua J. Oaks
Anna EiringAnna Eiring
Anna Eiring
MNMario Notari
Mario Notari
DPDanilo Perrotti
Danilo Perrotti
Blast crisis chronic myelogenous leukemia (CML-BC) and Philadelphia chromosome–positive (Ph1-positive) acute lymphocytic leukemia (ALL) are 2 fatal BCR/ABL-driven leukemias against which Abl kinase inhibitors fail to induce a long-term response. We recently reported that functional loss of protein phosphatase 2A (PP2A) activity is important for CML blastic transformation. We assessed the therapeutic potential of the PP2A activator FTY720 (2-amino-2-[2-(4-octylphenyl)ethyl]-1,3-propanediol hydrochloride), an immunomodulator in Phase III trials for patients with multiple sclerosis or undergoing organ transplantation, in CML-BC and Ph1 ALL patient cells and in in vitro and in vivo models of these BCR/ABL+ leukemias. Our data indicate that FTY720 induces apoptosis and impairs clonogenicity of imatinib/dasatinib-sensitive and -resistant p210/p190BCR/ABL myeloid and lymphoid cell lines and CML-BCCD34+ and Ph1 ALLCD34+/CD19+ progenitors but not of normal CD34+ and CD34+/CD19+ bone marrow cells. Furthermore, pharmacologic doses of FTY720 remarkably suppress in vivo p210/p190BCR/ABL-driven [including p210/p190BCR/ABL (T315I)] leukemogenesis without exerting any toxicity. Altogether, these results highlight the therapeutic relevance of rescuing PP2A tumor suppressor activity in Ph1 leukemias and strongly support the introduction of the PP2A activator FTY720 in the treatment of CML-BC and Ph1 ALL patients.

24 July 2012 in Nature Reviews Cancer
Verified
Journal Article
Closed access
TOThomas O'Hare
Thomas O'Hare
MZMatthew S. Zabriskie
Matthew S. Zabriskie
Anna EiringAnna Eiring
Anna Eiring
MDMichael W. Deininger
Michael W. Deininger

1 April 2010 in Cancer Cell
Verified
Journal Article
Closed access
SLShujun Liu
Shujun Liu
LWLai-Chu Wu
Lai-Chu Wu
JPJiuxia Pang
Jiuxia Pang
RSRamasamy Santhanam
Ramasamy Santhanam
SSSebastian Schwind
Sebastian Schwind
GMGuido Marcucci
Guido Marcucci

17 January 2013 in Blood
Verified
Journal Article
Open access
PDF file
JKJamshid S. Khorashad
Jamshid S. Khorashad
TKTodd W. Kelley
Todd W. Kelley
PSPhilippe Szankasi
Philippe Szankasi
CMClinton C. Mason
Clinton C. Mason
Simona SoveriniSimona Soverini
Simona Soverini
MDMichael Deininger
Michael Deininger
BCR-ABL1 compound mutations can confer high-level resistance to imatinib and other ABL1 tyrosine kinase inhibitors (TKIs). The third-generation ABL1 TKI ponatinib is effective against BCR-ABL1 point mutants individually, but remains vulnerable to certain BCR-ABL1 compound mutants. To determine the frequency of compound mutations among chronic myeloid leukemia patients on ABL1 TKI therapy, in the present study, we examined a collection of patient samples (N = 47) with clear evidence of 2 BCR-ABL1 kinase domain mutations by direct sequencing. Using a cloning and sequencing method, we found that 70% (33/47) of double mutations detected by direct sequencing were compound mutations. Sequential, branching, and parallel routes to compound mutations were common. In addition, our approach revealed individual and compound mutations not detectable by direct sequencing. The frequency of clones harboring compound mutations with more than 2 missense mutations was low (10%), whereas the likelihood of silent mutations increased disproportionately with the total number of mutations per clone, suggesting a limited tolerance for BCR-ABL1 kinase domain missense mutations. We conclude that compound mutations are common in patients with sequencing evidence for 2 BCR-ABL1 mutations and frequently reflect a highly complex clonal network, the evolution of which may be limited by the negative impact of missense mutations on kinase function.